BMS493 is an inverse agonist of pan-retinoic acid receptor (RAR). It increases the interaction of nuclear corepressors with RAR and can be used as an inhibitor of dietary and pharmacologically manipulated retinoic acid (RA) activity in vivo and in vitro.

 

Brand: BCM

 

Target: Retinoid Receptor

 

Signaling Pathways: Metabolism

 

In Vitro: BMS493 (100 nM; 6 days; ALDHhi UCB cells) treatment shows a twofold increase in the number of ALDHhi cells available for transplantation compared with untreated controls. Newly expanded ALDHhi cells shows increased numbers of CD34 and CD133-positive cells. As well as a reduction in CD38 expression, a marker of hematopoietic cell differentiation.

 

Boiling Point: 605.4±55.0 °C(Predicted)

 

pKa: 4.27±0.10(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

Isomeric SMILES: CC1(CC=C(C2=C1C=CC(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)C#CC4=CC=CC=C4)C  

 

InChIKey: YCADIXLLWMXYKW-CMDGGOBGSA-N  

 

InChI: InChI=1S/C29H24O2/c1-29(2)19-18-24(14-10-21-6-4-3-5-7-21)26-20-23(13-17-27(26)29)9-8-22-11-15-25(16-12-22)28(30)31/h3-9,11-13,15-18,20H,19H2,1-2H3,(H,30,31)/b9-8+ 

 

Attribute
[Chem Name]	4-[(E)-2-[5,5-dimethyl-8-(2-phenylethynyl)-6H-naphthalen-2-yl]ethenyl]benzoic acid
[Synonym]	BMS493; BMS 493; BMS-493
[CAS No.]	215030-90-3
[MDL No.]	MFCD17215944
[Formula]	C29H24O2
[Molecular]	404.5
[Form]	Light yellow to yellow powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag